Eleonora Cannas

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.

This paper develops a 3D co-culture system using bone marrow stromal cells to study drug resistance in B cell non-Hodgkin lymphoma and identifies potential resistance mediators.

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.